A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1698 participants.
Also called NCT06045221
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,698 participants
- Sponsor
- Registry
-
NCT06045221
-
- Other papers using this trial's data
- Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, China, Japan, Mexico, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT06045221. Randomized; no masking; primary purpose treatment. Start 2023-09-22 (actual); primary completion 2025-08-22 (actual). Results posted on 2026-09-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
- Acronym
- ACHIEVE-3
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Orforglipron
- Intervention (Drug)
- Semaglutide
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct06045221- Content hash
1c28f4582c463a5e2af342efb08a0d1fc515d0a876506a8900c7a9ed940afb81